Pramipexol Ferrer: Uses, Dosage & Side Effects
A non-ergot dopamine D2/D3 receptor agonist in once-daily prolonged-release tablets, used for the symptomatic treatment of idiopathic Parkinson's disease in adults
Pramipexol Ferrer is a generic prolonged-release formulation of pramipexole, a selective non-ergot dopamine agonist with high affinity for the dopamine D2 receptor subfamily, particularly the D3 subtype. It is licensed for the symptomatic treatment of idiopathic Parkinson's disease in adults, either as monotherapy in early disease or in combination with levodopa in later stages, when the effect of levodopa wears off or becomes erratic. The 0.26 mg prolonged-release tablet (corresponding to 0.375 mg of pramipexole salt) is the lowest dose strength and is used as the starting dose during treatment initiation. Once-daily dosing provides stable plasma concentrations across 24 hours, which can simplify treatment regimens and may reduce dyskinesias and motor fluctuations compared with immediate-release formulations.
Quick Facts: Pramipexol Ferrer
Key Takeaways
- Pramipexol Ferrer (pramipexole) is a non-ergot dopamine D2/D3 agonist licensed for the symptomatic treatment of idiopathic Parkinson's disease, alone or in combination with levodopa.
- The prolonged-release tablet is taken once daily, swallowed whole with water; it must not be chewed, divided, or crushed because this would destroy the controlled-release matrix.
- Treatment is started at 0.26 mg base once daily and titrated upward every 5–7 days as tolerated, to a recommended maximum of 3.15 mg base per day.
- Important risks include sudden onset of sleep without warning (sleep attacks), impulse control disorders such as pathological gambling and hypersexuality, hallucinations, and orthostatic hypotension, especially during dose titration.
- Pramipexole is excreted largely unchanged in urine; dose reduction or extended dosing intervals are required in moderate to severe renal impairment, and the drug must never be stopped abruptly because of the risk of dopamine agonist withdrawal syndrome and a neuroleptic malignant-like reaction.
What Is Pramipexol Ferrer and What Is It Used For?
Pramipexol Ferrer is a generic medicinal product whose active substance is pramipexole, in the form of pramipexole dihydrochloride monohydrate. Pramipexole belongs to a class of medicines known as non-ergot dopamine agonists. Unlike older ergoline-derived dopamine agonists such as bromocriptine, cabergoline, and pergolide, the non-ergot agonists do not contain an ergot ring system and therefore do not carry the same risk of cardiac valvulopathy or pleuropulmonary fibrosis. Pramipexole, ropinirole, rotigotine, and apomorphine are the principal members of this group used in clinical practice.
The 0.26 mg prolonged-release tablet (equivalent to 0.375 mg of the salt form) is the lowest available strength of pramipexole and is used during the initial titration phase of treatment. Higher strengths (0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, and 3.15 mg base) are available so that the daily dose can be reached using a single tablet once the optimum maintenance dose has been established. The prolonged-release matrix releases the active substance gradually over 24 hours, providing stable plasma concentrations that allow once-daily dosing.
Pramipexole acts by selectively binding to and activating the dopamine D2 receptor subfamily, with preferential affinity for the D3 receptor subtype. By stimulating dopamine receptors in the striatum (a region of the basal ganglia that controls movement), pramipexole partly compensates for the dopaminergic deficit that characterizes Parkinson's disease. The medicine also reduces dopaminergic neuron firing in the substantia nigra. Some preclinical studies have suggested possible neuroprotective properties through antioxidant and anti-apoptotic effects, although these have not been established conclusively in humans.
Parkinson's Disease
Parkinson's disease is a progressive neurodegenerative disorder that affects an estimated 8.5 million people worldwide, according to the World Health Organization. Its prevalence has more than doubled in the past 25 years and is expected to continue rising as populations age. The condition results from the gradual loss of dopamine-producing neurons in the substantia nigra pars compacta and from the accumulation of misfolded alpha-synuclein protein in characteristic Lewy bodies.
The cardinal motor symptoms of Parkinson's disease are bradykinesia (slowness of movement), rest tremor (typically a 4–6 Hz pill-rolling tremor of the hands), rigidity (increased muscle tone with cogwheel or lead-pipe quality), and, in later stages, postural instability. Many patients also experience non-motor features such as constipation, hyposmia (loss of sense of smell), REM sleep behaviour disorder, depression, anxiety, cognitive changes, autonomic dysfunction, and pain. Together, these symptoms have a profound impact on quality of life and independence.
Pramipexol Ferrer is approved for the symptomatic treatment of idiopathic Parkinson's disease in adults. It can be used in two main settings:
- Monotherapy in early disease: In patients with mild to moderate Parkinson's disease who do not yet require levodopa, dopamine agonists such as pramipexole can be used as initial therapy. This strategy may delay the introduction of levodopa and reduce the long-term risk of motor complications such as dyskinesia, although at the cost of greater non-motor side effects (somnolence, hallucinations, impulse control disorders, oedema). Choice of initial therapy should be individualized according to age, comorbidities, employment status, and patient preference.
- Combination therapy with levodopa: In patients with more advanced disease who experience “wearing-off” phenomena or motor fluctuations between levodopa doses, adding a dopamine agonist can smooth out the motor response, reduce the total daily levodopa requirement, and decrease “off” time. The prolonged-release formulation is particularly suited to patients who would benefit from a single daily dose with stable plasma concentrations.
Major international guidelines, including those from the National Institute for Health and Care Excellence (NICE) and the International Parkinson and Movement Disorder Society (MDS), recognize pramipexole as an evidence-based therapy for the motor symptoms of Parkinson's disease, both as monotherapy and as adjunctive therapy with levodopa.
Note on Restless Legs Syndrome
Immediate-release formulations of pramipexole are also licensed for the symptomatic treatment of moderate to severe primary restless legs syndrome (RLS) at lower doses (typically 0.088–0.54 mg base per day). However, the prolonged-release formulation of pramipexole, including Pramipexol Ferrer 0.26 mg prolonged-release tablets, is not indicated for restless legs syndrome in the European Union. Patients with RLS should be prescribed the immediate-release form or a different agent altogether. Long-term dopamine agonist therapy in RLS also carries a substantial risk of augmentation, in which the syndrome paradoxically worsens, occurs earlier in the day, and spreads to other body parts.
Pramipexol Ferrer is a generic medicine that has been demonstrated to be bioequivalent to the original reference product (Mirapexin/Sifrol prolonged-release). This means that the rate and extent of absorption of the active ingredient are clinically equivalent. However, because pramipexole is available as both salt (dihydrochloride monohydrate) and base, and because dosing is expressed in different ways across formulations and countries, switching between products should always be supervised by a clinician to avoid dosing errors. The convention used in this article and in the EU Summary of Product Characteristics is to express doses as pramipexole base.
What Should You Know Before Taking Pramipexol Ferrer?
Contraindications
There are very few absolute contraindications to pramipexole therapy, but they must be respected before treatment is initiated.
- Hypersensitivity: Do not take Pramipexol Ferrer if you are allergic (hypersensitive) to pramipexole or to any of the other ingredients of the tablets. Allergic reactions to oral pramipexole are rare but can include rash, urticaria, angioedema, and, very rarely, anaphylaxis.
Outside of true allergy, pramipexole has no other absolute contraindications, but several conditions and circumstances require dose adjustment, careful monitoring, or specialist input before treatment begins.
Warnings and Precautions
Pramipexole has been associated with somnolence and episodes of sudden onset of sleep, sometimes without prior warning signs. These can occur during activities of daily living, including driving, and have caused serious traffic accidents. Patients must not drive or operate machinery during treatment if they have experienced unusual drowsiness or have ever fallen asleep without warning. The risk is increased by concomitant use of other sedating medicines, alcohol, or sleep disorders. If sleep attacks occur, the dose should be reduced or treatment discontinued.
Patients receiving dopamine agonists, including pramipexole, may develop impulse control disorders (ICDs) such as pathological gambling, increased libido and hypersexuality, compulsive shopping or buying, binge or compulsive eating, and compulsive performance of repetitive activities (punding). Patients and their families should be regularly asked about these symptoms by the prescribing physician. Patients themselves often do not recognize their behaviour as abnormal. If an ICD develops, the dose should be reduced and discontinuation considered.
Before and during treatment with Pramipexol Ferrer, inform your doctor if any of the following apply to you:
- Kidney problems: Pramipexole is eliminated almost entirely by the kidneys. In patients with moderate to severe renal impairment, dose adjustments are essential to avoid drug accumulation and toxicity. Tell your doctor if you have ever had kidney disease, kidney failure, dialysis, or known reduced kidney function (low estimated glomerular filtration rate).
- Mental health conditions: Patients with a history of psychotic disorders, hallucinations, or paranoid symptoms should generally not be treated with dopamine agonists unless the potential benefits clearly outweigh the risks. Pramipexole can precipitate or worsen these symptoms.
- Low blood pressure or postural hypotension: Dopamine agonists can cause symptomatic orthostatic hypotension, particularly during dose initiation and titration. Get up slowly from a sitting or lying position. Tell your doctor about any episodes of dizziness, light-headedness, or fainting.
- Heart disease: Cardiovascular monitoring is recommended in patients with severe cardiovascular disease, especially during the early titration period.
- Eye problems: Visual disturbances and changes in vision have been reported. Eye examinations are recommended at regular intervals or if visual abnormalities occur.
- Severe systemic disease: Treatment may need to be reassessed in the presence of severe acute illness.
- History of compulsive behaviour or addiction: Tell your doctor if you, or someone in your family, has previously had problems with gambling, sexual compulsions, compulsive eating, or other compulsive behaviours, as this may increase the risk of impulse control disorders during treatment.
- Augmentation phenomena: Although augmentation is mostly reported in the context of restless legs syndrome, it has been recognized that long-term dopaminergic stimulation can cause complex motor and behavioural changes. Report any new or worsening symptoms.
- Dyskinesias: When pramipexole is added to levodopa, pre-existing dyskinesias may worsen during initial titration. The dose of levodopa may need to be reduced.
- Dopamine agonist withdrawal syndrome (DAWS): Abrupt discontinuation or rapid dose reduction of pramipexole can cause anxiety, depression, fatigue, sweating, insomnia, pain, dizziness, and drug cravings. Pramipexole should always be tapered gradually under medical supervision.
A symptom complex resembling neuroleptic malignant syndrome (high fever, muscle rigidity, altered mental status, autonomic instability, raised creatine kinase) has been reported with abrupt withdrawal of dopaminergic therapy in patients with Parkinson's disease. This is a medical emergency. Pramipexol Ferrer should never be stopped suddenly; the dose must be reduced gradually under medical supervision.
Use in the Elderly
The clearance of pramipexole decreases with age, so plasma concentrations are higher and the elimination half-life is longer in elderly patients (approximately 12–14 hours, compared with about 8 hours in younger adults). However, dose adjustment is generally not required in elderly patients with normal renal function. Caution is needed because older patients are more vulnerable to side effects such as hallucinations, confusion, postural hypotension, and somnolence. The lowest effective dose should be used.
Use in Children and Adolescents
The safety and efficacy of pramipexole in children and adolescents below 18 years of age have not been established. Pramipexol Ferrer is not indicated in this age group.
Pregnancy and Breastfeeding
The effect of pramipexole on human pregnancy has not been investigated in well-controlled studies. Animal studies have shown reproductive toxicity at maternally toxic doses. Pramipexol Ferrer should not be used during pregnancy unless clearly necessary, that is, when the potential benefit justifies the potential risk to the fetus. Women of childbearing potential should use effective contraception during treatment, and any planned pregnancy should be discussed with the treating neurologist.
Pramipexole inhibits the secretion of prolactin in humans and is therefore expected to inhibit lactation. The drug is excreted in the breast milk of animals; in humans, it is not known whether pramipexole passes into breast milk in clinically significant amounts. Because of the potential for serious adverse effects in nursing infants, breastfeeding is not recommended while taking Pramipexol Ferrer. If the use of pramipexole is unavoidable, breastfeeding should be discontinued.
Driving and Operating Machinery
Pramipexol Ferrer can have a major influence on the ability to drive and use machines. Hallucinations and somnolence can occur. Patients receiving pramipexole who experience somnolence or sudden sleep onset must refrain from driving or engaging in activities (for example, operating machines) where impaired alertness may put themselves or others at risk of serious injury or death until such recurrent episodes and somnolence have resolved. Patients should not drive or operate complex machinery until they have gained sufficient experience with Pramipexol Ferrer to gauge whether or not it adversely affects their mental and motor performance.
Important Information About Ingredients
Pramipexol Ferrer prolonged-release tablets contain a number of inactive excipients. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine if it contains relevant sugars. Always check the package leaflet for the complete list of excipients in your specific batch. The product does not contain lactose in the prolonged-release formulation, but formulations may vary by manufacturer.
How Does Pramipexol Ferrer Interact with Other Drugs?
Pramipexole undergoes minimal hepatic metabolism and is excreted largely unchanged by the kidneys via the organic cation transport system, particularly the OCT2 transporter. As a result, it is not affected by inhibitors or inducers of cytochrome P450 enzymes, which are the dominant pathway for many other neurological medicines. The clinically important drug interactions with pramipexole are therefore concentrated in three groups: drugs that compete for renal tubular secretion, drugs that act on dopamine receptors, and drugs that depress the central nervous system.
Major Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Cimetidine | Inhibits renal cation transport, decreases pramipexole clearance by approximately 34% and increases half-life by ~40% | Monitor for increased side effects (nausea, hallucinations, dyskinesia); consider dose reduction |
| Antipsychotics (e.g., haloperidol, risperidone, olanzapine) | Block dopamine D2 receptors and may antagonise the therapeutic effect of pramipexole | Combination should generally be avoided; if antipsychotic is essential, prefer agents with low D2 affinity (e.g., quetiapine, clozapine) |
| Antiemetics (metoclopramide, prochlorperazine) | Block central dopamine receptors, may worsen Parkinson's symptoms and reduce pramipexole efficacy | Avoid; use peripherally acting antiemetics such as domperidone (with QT precautions) or ondansetron instead |
| Levodopa | Additive dopaminergic effect; may worsen orthostatic hypotension, dyskinesias, hallucinations, and somnolence | Frequently combined intentionally; the levodopa dose may need to be reduced when pramipexole is added |
| Sedatives, hypnotics, opioids, alcohol | Additive central nervous system depression; increased risk of somnolence and sleep attacks | Use with caution; warn patients about driving and machinery; avoid alcohol |
Other Interactions
| Interacting Drug | Effect | Clinical Significance |
|---|---|---|
| Amantadine | Both compete for renal tubular secretion; theoretical risk of higher pramipexole levels and additive side effects | Monitor clinically; combination is commonly used in Parkinson's disease |
| Selegiline, rasagiline, safinamide (MAO-B inhibitors) | Additive dopaminergic effect, possible increase in dyskinesias | Combination is acceptable and frequently used; monitor for side effects |
| Antihypertensives | Additive risk of orthostatic hypotension | Monitor blood pressure carefully, especially during titration |
| Other dopamine agonists | Combined dopaminergic stimulation increases the risk of side effects such as hallucinations and impulse control disorders | Combinations of two oral dopamine agonists are generally not recommended |
| Drugs eliminated via OCT2 (e.g., procainamide, ranitidine) | Theoretical competition for renal cation transport | Clinical significance limited; monitor for additive effects |
Always inform every doctor and pharmacist who prescribes or dispenses medicines for you that you are taking Pramipexol Ferrer. This includes when buying over-the-counter products, herbal remedies (such as St John's wort), or food supplements, and before any planned surgery, dental procedure, or imaging investigation that may require sedation. Avoid alcohol throughout treatment.
What Is the Correct Dosage of Pramipexol Ferrer?
Pramipexol Ferrer is a once-daily prolonged-release tablet. It must be swallowed whole with a glass of water and must not be chewed, divided, or crushed, because doing so would damage the controlled-release matrix and release the entire dose immediately, dramatically increasing the risk of side effects. The tablet may be taken with or without food. To help maintain stable plasma levels, it should be taken at approximately the same time each day. If a patient cannot swallow whole tablets, an alternative formulation (immediate-release pramipexole) should be used at an equivalent total daily dose, divided over three administrations.
Adults – Initial Treatment and Titration
Standard Dose Titration Schedule (Pramipexole Base)
Doses are increased every 5–7 days according to clinical response and tolerability. Each step doubles the daily dose, with the goal of reaching the lowest effective dose for symptom control.
| Week | Daily Dose (Base) | Daily Dose (Salt) | Number of 0.26 mg Tablets |
|---|---|---|---|
| Week 1 (initial) | 0.26 mg | 0.375 mg | 1 tablet |
| Week 2 | 0.52 mg | 0.75 mg | 2 tablets (or 1 × 0.52 mg) |
| Week 3 | 1.05 mg | 1.5 mg | 1 × 1.05 mg tablet |
| Further titration | +0.52 mg per week | +0.75 mg per week | Switch to higher-strength tablets |
| Maximum | 3.15 mg | 4.5 mg | 1 × 3.15 mg tablet |
Most patients achieve good symptom control between 1.05 mg and 3.15 mg base per day. The lowest effective dose should be maintained, balancing symptomatic benefit against the risk of side effects. If a patient is being switched from immediate-release pramipexole, they may transition overnight at the same total daily dose; for example, three 0.26 mg immediate-release tablets per day (0.78 mg base/day) would be replaced by one prolonged-release tablet of approximately equivalent strength on the next morning.
Use in Combination with Levodopa
When pramipexole is added to existing levodopa therapy, the levodopa dose may need to be reduced (typically by 10–30%) to manage the additive dopaminergic effect. This is particularly important in patients with established dyskinesias, which may worsen during the initial titration of pramipexole. The reduction should be made gradually, under specialist supervision, and titrated against the patient's symptoms.
Renal Impairment
Because pramipexole is excreted almost entirely unchanged in urine, dose adjustment is essential in patients with reduced kidney function.
| Creatinine Clearance | Renal Function | Recommended Approach |
|---|---|---|
| > 50 mL/min | Normal to mildly reduced | Standard dosing – no adjustment required |
| 30–50 mL/min | Moderate impairment | Start with 0.26 mg base every other day; titrate cautiously based on tolerability and effect |
| < 30 mL/min | Severe impairment | Prolonged-release form is generally not recommended; use immediate-release at reduced dose under specialist supervision |
| Dialysis | End-stage renal disease | Use of pramipexole has not been adequately studied; treatment should be individualized by a specialist |
Hepatic Impairment
Because the contribution of liver metabolism to the elimination of pramipexole is minimal, no dose adjustment is required in patients with hepatic impairment.
Elderly Patients
No dose adjustment is required for elderly patients with normal renal function. However, because creatinine clearance decreases with age, kidney function should be checked before treatment and periodically thereafter, with dose adjustment if renal function declines. The lowest effective dose should be used, given the higher susceptibility of elderly patients to hallucinations, postural hypotension, and somnolence.
Children and Adolescents
Pramipexol Ferrer should not be used in children or adolescents below the age of 18 years, because safety and efficacy in this age group have not been established and Parkinson's disease is extremely rare in this population.
If You Forget a Dose
If you forget to take your daily dose of Pramipexol Ferrer, take it within 12 hours of the usual time. If more than 12 hours have passed, skip the missed dose and take your next dose at the usual time the following day. Do not take a double dose to make up for a forgotten one, because this would substantially increase the risk of side effects, particularly nausea, somnolence, and orthostatic hypotension.
Overdose
There is no clinical experience with massive overdose of pramipexole. Anticipated symptoms would be related to the pharmacological action of the drug: nausea, vomiting, hyperkinesia, hallucinations, agitation, and hypotension. There is no specific antidote. If unwarranted central nervous system stimulation occurs, a neuroleptic agent may be considered, but the risk of dopamine antagonism in a patient with Parkinson's disease must be weighed carefully. Management is supportive and includes general supportive measures, gastric lavage, intravenous fluids, charcoal administration, and electrocardiographic monitoring. Always seek immediate medical attention if an overdose is suspected.
Stopping Treatment
Pramipexol Ferrer must never be stopped abruptly. Sudden discontinuation can trigger a neuroleptic malignant-like syndrome and dopamine agonist withdrawal syndrome (DAWS). Treatment should be tapered at a rate of 0.52 mg base per day until the daily dose has been reduced to 0.52 mg base. The dose should then be reduced by 0.26 mg base per day until discontinuation. This taper should be supervised by your treating doctor.
What Are the Side Effects of Pramipexol Ferrer?
Like all medicines, Pramipexol Ferrer can cause side effects, although not everybody gets them. Most adverse effects are dose-related and tend to be more pronounced during the initial weeks of treatment and during dose titration. Many patients tolerate the medicine well in the long term, particularly if the lowest effective dose is identified. The frequencies below are based on the European Medicines Agency Summary of Product Characteristics for prolonged-release pramipexole and on data pooled from controlled clinical trials.
Very Common Side Effects
Affecting more than 1 in 10 people
- Dyskinesia – involuntary, often irregular movements; particularly when used in combination with levodopa
- Somnolence – excessive daytime drowsiness or sleepiness
- Dizziness
- Nausea – usually transient, more common during titration
Common Side Effects
Affecting up to 1 in 10 people
- Insomnia and abnormal dreams
- Headache, fatigue
- Constipation, vomiting
- Hallucinations (most often visual)
- Confusion, restlessness
- Postural (orthostatic) hypotension – dizziness on standing
- Peripheral oedema – swelling of the ankles or legs
- Visual impairment, blurred vision
- Decreased appetite, weight decrease
- Hiccups, dyspnoea (shortness of breath)
Uncommon Side Effects
Affecting up to 1 in 100 people
- Sudden onset of sleep, sleep attacks
- Paranoid ideation, delusions
- Impulse control disorders: pathological gambling, hypersexuality, compulsive buying, binge eating, punding (compulsive repetitive behaviours)
- Hyperphagia (compulsive eating)
- Amnesia (memory problems)
- Hyperkinesia, agitation, libido disorders
- Heart failure (in patients with risk factors)
- Pneumonia
- Weight increase
- Hypersensitivity reactions: rash, pruritus (itching)
Rare Side Effects
Affecting up to 1 in 1,000 people
- Inappropriate antidiuretic hormone secretion (SIADH) leading to hyponatraemia
- Mania
Not Known (Frequency Cannot Be Estimated)
Reported in post-marketing surveillance
- Dopamine agonist withdrawal syndrome (DAWS) on dose reduction or discontinuation: anxiety, depression, fatigue, sweating, pain, drug cravings
- Neuroleptic malignant-like syndrome on abrupt withdrawal
- Aggression
- Falls associated with sleep attacks or hypotension
Managing Common Side Effects
Nausea is one of the most common reasons for stopping pramipexole during the first weeks. It usually improves with continued treatment but can be reduced by taking the tablet with food, by slowing the rate of dose escalation, and, when needed, by short-term use of a peripheral antiemetic such as domperidone. Centrally acting antiemetics such as metoclopramide and prochlorperazine should be avoided because they antagonise dopamine receptors and can worsen Parkinson's symptoms.
Somnolence and sudden sleep attacks warrant particular attention. All patients should be specifically warned about this risk before starting therapy and asked at every clinic visit. Patients should not drive or operate machinery until they have established that pramipexole does not cause inappropriate drowsiness. If sleep attacks occur, the dose should be reduced and, if necessary, treatment discontinued.
Hallucinations and confusion occur in around 5–10% of patients and are more common in older patients, those with cognitive impairment, and those receiving higher doses or combinations with levodopa. Visual hallucinations of small animals, children, or familiar people are typical. Initial management includes reducing or simplifying the antiparkinsonian regimen; in severe cases, low-dose quetiapine or clozapine can be considered under specialist care.
Impulse Control Disorders
Impulse control disorders deserve detailed discussion because they can have catastrophic personal and financial consequences and are often missed unless directly asked about. Studies suggest that up to 17% of patients on dopamine agonists develop one or more impulse control disorders, with higher risk among younger patients, men (for hypersexuality), women (for compulsive shopping), and patients with a personal or family history of obsessive-compulsive traits, addiction, or depression.
Patients and their families should be specifically asked about new patterns of gambling, online or in-person, and about hypersexual behaviour, compulsive online shopping, binge eating, or repetitive purposeless activities such as constantly disassembling and reassembling household items (punding). At-risk individuals should be identified before treatment if possible. If symptoms develop, the dose of pramipexole should be reduced gradually and, in many cases, the medicine discontinued, with switching to an alternative such as levodopa monotherapy. Cognitive behavioural therapy and family support are also useful.
Reporting Side Effects
If you experience any side effects, talk to your doctor or pharmacist, including any possible side effects not listed in this article or in the package leaflet. You can also report side effects directly via national pharmacovigilance systems, such as the Yellow Card Scheme in the United Kingdom, the FDA MedWatch program in the United States, or your national medicines agency in other European countries. Reporting suspected adverse reactions after authorisation of the medicinal product is important to allow continued monitoring of the benefit–risk balance.
How Should You Store Pramipexol Ferrer?
Correct storage of Pramipexol Ferrer helps to maintain the stability and effectiveness of the prolonged-release tablets throughout their shelf life. Pramipexole is a stable compound, but moisture can degrade the controlled-release coating and lead to unpredictable absorption.
- Temperature: Store below 30 °C. Do not freeze.
- Light and moisture: Keep the tablets in the original blister pack to protect them from moisture and light. Do not transfer tablets to a pillbox unless you can ensure dry, opaque storage and identify each strength clearly.
- Out of reach of children: Keep this medicine out of the sight and reach of children. Even small numbers of tablets can be dangerous if accidentally swallowed by a child.
- Expiry date: Do not use Pramipexol Ferrer after the expiry date stated on the carton and blister. The expiry date refers to the last day of that month.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to dispose of any unwanted Pramipexol Ferrer tablets. These measures will help to protect the environment and prevent unintended exposure of others, including children, pets, and the general environment, to potent dopaminergic medicines.
What Does Pramipexol Ferrer Contain?
Active Ingredient
The active substance in Pramipexol Ferrer is pramipexole, present in the tablets as pramipexole dihydrochloride monohydrate. Each prolonged-release tablet of Pramipexol Ferrer 0.26 mg contains 0.375 mg of pramipexole dihydrochloride monohydrate, which corresponds to 0.26 mg of pramipexole base. The Summary of Product Characteristics expresses doses as the base form, in line with the EU convention for pramipexole.
Other Ingredients (Excipients)
The exact composition of excipients may vary slightly from one generic manufacturer to another, but the prolonged-release matrix typically contains:
- Hypromellose – the principal matrix-forming polymer that controls the release of the active ingredient over 24 hours
- Maize (corn) starch
- Carbomer
- Colloidal anhydrous silica
- Magnesium stearate – used as a lubricant during tablet compression
The tablets do not normally contain lactose, gluten, or sucrose. Patients with confirmed allergies to any specific excipient should always check the package leaflet supplied with their pack, as formulations may be updated by the manufacturer.
Appearance and Pack Sizes
Pramipexol Ferrer 0.26 mg prolonged-release tablets are typically white to off-white, round, biconvex tablets, presented in PVC/aluminium blister packs. Pack sizes commonly available include 10, 30, 100 tablets, although availability varies by country. Always refer to the carton or your pharmacist for the exact appearance, identification marks, and pack size of your prescription.
Marketing Authorisation Holder
Pramipexol Ferrer is manufactured and marketed by Ferrer Internacional, S.A., a Spanish pharmaceutical company headquartered in Barcelona, with subsidiaries and partnerships in numerous countries. Pramipexole was originally developed by Boehringer Ingelheim under the brand names Mirapexin and Sifrol in Europe and Mirapex in the United States. Generic versions of pramipexole, including Pramipexol Ferrer, became available after expiry of the original patents and have allowed broader access to this important Parkinson's medicine at lower cost.
Frequently Asked Questions About Pramipexol Ferrer
Pramipexol Ferrer prolonged-release tablets contain pramipexole, a non-ergot dopamine agonist used for the symptomatic treatment of idiopathic Parkinson's disease in adults. It can be used as monotherapy in early disease (without levodopa) or as add-on therapy together with levodopa in advanced disease, when levodopa effects begin to wear off or become inconsistent. Pramipexole helps reduce the motor symptoms of Parkinson's disease such as tremor, stiffness (rigidity), slowness of movement (bradykinesia), and postural instability.
Pramipexol Ferrer prolonged-release tablets are taken once daily, at approximately the same time each day. Swallow the tablet whole with a glass of water. Do not chew, divide, or crush the tablet, as this would damage the controlled-release mechanism and could release the entire dose at once. The tablet may be taken with or without food, although taking it with food may reduce nausea. Treatment is started at a low dose (0.26 mg once daily) and gradually increased every 5–7 days according to your response and tolerability, up to a maximum of 3.15 mg once daily.
The most common side effects of pramipexole include nausea, dizziness, somnolence (excessive daytime sleepiness), constipation, headache, fatigue, and dyskinesia (involuntary movements, particularly when used in combination with levodopa). Less common but clinically important effects include hallucinations, abnormal dreams, peripheral oedema, postural hypotension (dizziness on standing), sudden onset of sleep, and impulse control disorders such as pathological gambling, hypersexuality, or compulsive shopping or eating. Most side effects are dose-related and tend to improve with dose reduction or to settle with continued treatment.
Yes. Pramipexole has been associated with somnolence and episodes of sudden onset of sleep, occasionally without warning prodromal signs. These can occur during activities of daily living, including driving, and have caused traffic accidents. Patients must be informed of this risk and advised not to drive or operate machinery if they have experienced somnolence or sudden sleep episodes. The risk is increased by concomitant use of other sedating medications or alcohol. If sleep attacks occur, the dose should be reduced or treatment discontinued under medical supervision.
Impulse control disorders (ICDs) are behavioural disturbances reported in patients receiving dopamine agonists, including pramipexole. They include pathological gambling, increased libido and hypersexuality, compulsive shopping or buying, binge or compulsive eating, and compulsive performance of repetitive activities (punding). The risk appears higher with higher doses and longer treatment, and in patients with a personal or family history of compulsive behaviours. Patients and their families should be regularly asked about these symptoms, as patients themselves may not recognize the behaviour as abnormal. If an ICD develops, dose reduction or gradual discontinuation should be considered.
No. Pramipexole should not be stopped abruptly. Sudden discontinuation can trigger a neuroleptic malignant-like syndrome with high fever, muscle rigidity, altered mental status, and autonomic instability. It can also lead to dopamine agonist withdrawal syndrome (DAWS), characterized by anxiety, depression, fatigue, insomnia, sweating, pain, and drug cravings. Treatment should be tapered gradually under medical supervision, typically by 0.52 mg base per day until reaching a daily dose of 0.52 mg base, after which the dose is reduced by 0.26 mg per day until discontinuation.
The effect of pramipexole on human pregnancy has not been established. Animal studies have shown reproductive toxicity at maternally toxic doses. Pramipexol Ferrer should not be used during pregnancy unless clearly necessary and after a careful benefit-risk assessment by a specialist. Because pramipexole inhibits the secretion of prolactin, it is expected to inhibit lactation. The drug is excreted in breast milk in animals; in humans, breastfeeding is therefore not recommended during treatment with pramipexole.
Alcohol should be avoided or strictly limited while taking Pramipexol Ferrer. Alcohol enhances the central nervous system depressant effects of pramipexole, increasing the risk of drowsiness, sudden sleep attacks, dizziness, and falls. Alcohol may also worsen orthostatic hypotension. If you choose to drink alcohol, do so only occasionally and in small amounts, and never before driving or operating machinery.
If you forget to take your daily dose of Pramipexol Ferrer, take it within 12 hours of the usual time. If more than 12 hours have passed, skip the missed dose and take your next dose at the usual time the following day. Do not take a double dose to make up for a forgotten one, because this would substantially increase the risk of nausea, somnolence, and orthostatic hypotension. If you regularly forget doses, talk to your doctor or pharmacist about strategies such as pill organisers, reminders, or family support.
No. Pramipexole is a symptomatic treatment, not a cure. It improves the motor symptoms of Parkinson's disease (tremor, stiffness, slowness, and postural instability) by stimulating dopamine receptors in the brain, but it does not stop or reverse the underlying loss of dopamine-producing neurons. There is currently no proven disease-modifying treatment for Parkinson's disease, although intensive research into neuroprotective therapies is ongoing worldwide. Continued treatment with pramipexole, levodopa, and other antiparkinsonian medicines remains essential to maintain quality of life.
References
- European Medicines Agency. Pramipexole – Summary of Product Characteristics (SmPC) for prolonged-release tablets. EMA, 2025. Available at: www.ema.europa.eu
- U.S. Food and Drug Administration. Mirapex ER (pramipexole dihydrochloride) extended-release tablets – Prescribing Information. FDA, 2024. Available at: www.accessdata.fda.gov
- Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease. Movement Disorders. 2018;33(8):1248–1266. doi:10.1002/mds.27372
- National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults: diagnosis and management. NICE guideline NG71. London: NICE, 2024.
- Hauser RA, Schapira AHV, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Movement Disorders. 2010;25(15):2542–2549. doi:10.1002/mds.23317
- Schapira AHV, Barone P, Hauser RA, et al. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011;77(8):767–774. doi:10.1212/WNL.0b013e31822affb0
- Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Archives of Neurology. 2010;67(5):589–595. doi:10.1001/archneurol.2010.65
- Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. Archives of Neurology. 2010;67(1):58–63. doi:10.1001/archneurol.2009.294
- World Health Organization. Parkinson disease – Fact sheet. Geneva: WHO, 2023. Available at: www.who.int
- British National Formulary (BNF). Pramipexole monograph. London: BMJ Group and Pharmaceutical Press, 2025. Available at: bnf.nice.org.uk
- Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021;397(10291):2284–2303. doi:10.1016/S0140-6736(21)00218-X
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team in accordance with our editorial standards. All content is based on peer-reviewed evidence, official regulatory documents, and international clinical guidelines.
Author
iMedic Medical Editorial Team — Specialists in Clinical Pharmacology and Neurology
Medical Reviewer
iMedic Medical Review Board — Independent panel of board-certified physicians
Evidence Level
Level 1A — Systematic reviews and randomized controlled trials
Last Reviewed
27 December 2025 — Reviewed against EMA SmPC, FDA label, MDS and NICE guidelines
For full details of our editorial process, fact-checking standards, and conflict-of-interest policy, see our Editorial Standards page.